Cadrenal Therapeutics Announces Appointment of Douglas Losordo, MD as Chief Medical Officer
PONTE VEDRA, Florida – July 25, 2022 –Cadrenal Therapeutics, Inc. (“Cadrenal”), a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug indication, today announced the appointment of Douglas W. Losordo, MD, FACC, FAHA as Chief Medical Officer.
Quang Pham, CEO of Cadrenal Therapeutics, stated, “As we prepare our Phase 3 trial for our lead drug candidate, tecarfarin, a novel cardiorenal therapy with orphan drug indication for the prevention of systemic thromboembolism in patients with end-stage renal disease and atrial fibrillation, we are extremely pleased to have Dr. Losordo join the Cadrenal team to help lead our development efforts. Dr. Losordo’s career has been dedicated to the development of novel therapeutics aimed at the reversal of chronic conditions such as refractory angina, critical limb ischemia, coronary microvascular dysfunction and heart failure. We look forward to his leadership and direction as we advance tecarfarin through the clinic.”
Losordo joins Cadrenal from American Regent, Inc., where he served as Global Head Clinical Research, Development and Operations. American Regent, a Daiichi Sankyo Group Company, develops, manufactures, and supplies high quality sterile injectables for healthcare providers, clinics and hospitals across the United States and Canada. Prior to American Regent, he served as Chief Medical Officer from 2020 to 2021 of KBP Biosciences, a clinical-stage biotechnology company dedicated to research, development, and commercialization of innovative medicines for the global market. Prior to KBP, he served as Executive Vice President, Global Head of Research and Development and Chief Medical Officer of Caladrius Biosciences (NASDAQ: CLBS) since 2013 and was a member of the Company’s Scientific Advisory Board from 2006 to 2013. Prior to Caladrius, he was Vice President, New Therapies Development, Regenerative Medicine, and a member of the Baxter Ventures team at Baxter International.
Before beginning his career in the biotech industry in 2011, Dr. Losordo was the director of the Feinberg Cardiovascular Research Institute and the Eileen M. Foell Professor of Heart Research at Northwestern University’s School of Medicine and director of the Program in Cardiovascular Regenerative Medicine at Northwestern Memorial Hospital. He is board-certified in internal medicine, cardiovascular disease, and interventional cardiology. He received his M.D. from the University of Vermont. He has served as an associate editor of Circulation Research, the basic science journal of the American Heart Association, and serves on the editorial boards of a number of scientific journals.
Dr. Losordo commented, “I am excited to be joining Cadrenal during this pivotal time as we prepare for our upcoming pivotal phase 3 trial. I look forward to the opportunity to bring this novel therapy to the market to help improve the lives of the thousands of individuals who suffer from this very serious condition.”
Cadrenal Therapeutics is focused on developing tecarfarin, a novel cardiorenal therapy with orphan drug designation for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease, or ESRD, and atrial fibrillation (irregular heartbeat), or AFib. Tecarfarin is a Vitamin K antagonist oral anticoagulant designed to target a different pathway than the most commonly prescribed drugs used in the treatment of thrombosis and AFib. Tecarfarin is Phase-3 ready and has been evaluated in eleven (11) human clinical trials and over 1,003 individuals. For more information, please visit: www.cadrenal.com.